Tools
Stock profile

EXAGEN INC. (XGN)

XGN · Latest close $3.90 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$3.90
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
1
vs previous quarter

EXAGEN INC. (XGN) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($568.7K bought vs $1.2M sold). Latest close $3.90 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-664.9K
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

RTW Investments · Perceptive Advisors · First Eagle Investment Management — 3 tracked funds hold XGN. See all holders.

Insider and Congress activity

Insiders bought on the open market (4 purchases, $568.7K) vs 5 sales ($1.2M). Latest buy: Nov 11, 2026. Insider trading

Often held alongside

Axogen, Inc. (AXGN) · Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RTW Investments0.01%195,000TRIMMED (-50.7%) Q3 filed Nov 16
Perceptive Advisors0.01%114,893HELD Q3 filed Nov 16
First Eagle Investment Management<0.01%306,965ADDED (+145.1%) Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -20.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

11.962.282024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding57 of 8,857 filers
Long-only filers among them57
Change vs 2026 Q1-1 net · 56 entered · 57 exited
Shares reported, all filers7,947,970
Reported value, all filers$34.4M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryServices-Medical Laboratories (SIC 8071)
Revenue · FY2025$66.6M
Net income · FY2025$-20.0M
Total assets · FY2025$58.0M
Shares outstanding24,225,339
Market cap (at latest close)$94.5M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.

Short interest

Shares short · Oct 15, 2026673,850
Share of shares outstanding2.78%
Days to cover1.82

Shares short at recent settlements — Jul 31, 2026: 904K · Aug 14, 2026: 940K · Aug 31, 2026: 864K · Sep 15, 2026: 800K · Sep 30, 2026: 705K · Oct 15, 2026: 674K.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (4 purchases, $568.7K), against 5 sales by 3 insiders ($1.2M). Latest buy: Nov 11, 2026.

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Chernett Jorey · 71,315 shares on Nov 11, 2026 · filed Nov 12, 2026$5.23-9.0% (close Nov 13, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Nov 13, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 13, 2026Chernett JoreySell58,068$4.08$236.9KSEC filing
Nov 12, 2026Chernett JoreySell109,436$4.65$508.9KSEC filing
Nov 11, 2026Chernett JoreyBuy71,315$5.23$373.0KSEC filing
Nov 10, 2026Chernett JoreyBuy7,085$5.26$37.3KSEC filing
Nov 9, 2026Chernett JoreyBuy8,500$6.35$54.0KSEC filing
Nov 6, 2026Chernett JoreySell11,265$6.14$69.2KSEC filing
Oct 19, 2026Chernett JoreyBuy14,000$7.46$104.4KSEC filing
Oct 16, 2026ABALLI JOHNPresident and CEOSell34,294$7.87$269.8KSEC filing
Sep 1, 2026Black Jeffrey G.Chief Financial OfficerSell20,614$7.22$148.8KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 8, 2024Adawi KamalOfficer84,162$247.4KOct 8, 2024SEC filing
Aug 9, 2024Adawi KamalOfficer52,624$145.2KAug 9, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 27, 2026Parian Ultreia LPSC 13G1,292,0005.3%May 22, 2026SEC filing
May 20, 2026Chernett JoreySC 13G/A2,413,9019.9%Mar 31, 2026SEC filing
Feb 17, 2026RTW Investments, LPSC 13G/A1,148,7684.9%Dec 31, 2025SEC filing
Feb 11, 2026NMSIC Co-Investment Fund, L.P.SC 13G/A1,368,9586.0%Dec 31, 2025SEC filing
Feb 4, 2026Chernett JoreySC 13G1,231,4385.4%Jan 30, 2026SEC filing
Aug 14, 2025RTW Investments, LPSC 13G/A1,696,8667.7%Jun 30, 2025SEC filing
Aug 14, 2025LYTTON LAURENCE WSC 13G/A216,8401.0%Jun 30, 2025SEC filing
May 12, 2025Cowen Financial Products LLCSC 13G/A891,3665.0%Mar 31, 2025SEC filing
Apr 17, 2025NMSIC Co-Investment Fund, L.P.SC 13G/A1,758,9589.8%Mar 25, 2025SEC filing
Jan 29, 2025NMSIC Co-Investment Fund, L.P.SC 13G/A2,108,95812.0%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Services-Medical Laboratories (SIC 8071). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 6 Lobbying Disclosure Act filings named this company as client, 2021–2022; most common issues: Medical/Disease Research/Clinical Labs (6).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Gross Profitability (Novy-Marx) — Gross profit / assets: 66.9% · Gross margin: 58.3%

· Distress Risk (Altman Z″) — Z″-Score: -14.91 · Working capital / assets: 0.60 · Retained earnings / assets: -5.42 · EBIT / assets: -0.24 · Equity / liabilities: 0.43

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold XGN — ranked by lift, the co-holding pattern described in Methodology: Axogen, Inc. (AXGN) · Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · QUEST DIAGNOSTICS INC (DGX) · BillionToOne, Inc. (BLLN) · CareDx, Inc. (CDNA).

7 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 10, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jun 9, 20265.07 Submission of Matters to a Vote of Security HoldersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Axogen, Inc. (AXGN) · Track Record: how the signals scored · Practice timing on XGN

One email a week: the week’s new filings and research. Subscribe free

← XFOR  ·  XLO →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.